BG101711A - Di-substituted 1,4-piperidine esters and amides having 5-ht4 antagonistic activity - Google Patents
Di-substituted 1,4-piperidine esters and amides having 5-ht4 antagonistic activityInfo
- Publication number
- BG101711A BG101711A BG101711A BG10171197A BG101711A BG 101711 A BG101711 A BG 101711A BG 101711 A BG101711 A BG 101711A BG 10171197 A BG10171197 A BG 10171197A BG 101711 A BG101711 A BG 101711A
- Authority
- BG
- Bulgaria
- Prior art keywords
- amides
- substituted
- antagonistic activity
- piperidine
- piperidine esters
- Prior art date
Links
- FUFZNHHSSMCXCZ-UHFFFAOYSA-N 5-piperidin-4-yl-3-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazole Chemical class FC(F)(F)C1=CC=CC(C=2N=C(ON=2)C2CCNCC2)=C1 FUFZNHHSSMCXCZ-UHFFFAOYSA-N 0.000 title abstract 2
- 150000001408 amides Chemical class 0.000 title abstract 2
- 230000003042 antagnostic effect Effects 0.000 title 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000003523 serotonin 4 antagonist Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT95MI000491A IT1275903B1 (it) | 1995-03-14 | 1995-03-14 | Esteri e ammidi della 1,4-piperidina disostituita |
| PCT/EP1996/000903 WO1996028424A1 (en) | 1995-03-14 | 1996-03-04 | Di-substituted 1,4-piperidine esters and amides having 5-ht4 antagonistic activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG101711A true BG101711A (en) | 1998-02-27 |
Family
ID=11370883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG101711A BG101711A (en) | 1995-03-14 | 1997-07-01 | Di-substituted 1,4-piperidine esters and amides having 5-ht4 antagonistic activity |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US6002009A (cs) |
| EP (1) | EP0815080B1 (cs) |
| JP (1) | JP4021477B2 (cs) |
| KR (1) | KR19980702972A (cs) |
| AR (1) | AR002967A1 (cs) |
| AT (1) | ATE269304T1 (cs) |
| AU (1) | AU5101096A (cs) |
| BG (1) | BG101711A (cs) |
| BR (1) | BR9607347A (cs) |
| CA (1) | CA2209904C (cs) |
| CO (1) | CO4700521A1 (cs) |
| CZ (1) | CZ285997A3 (cs) |
| DE (1) | DE69632724T2 (cs) |
| EE (1) | EE9700202A (cs) |
| ES (1) | ES2224159T3 (cs) |
| HR (1) | HRP960116A2 (cs) |
| IL (1) | IL117446A0 (cs) |
| IT (1) | IT1275903B1 (cs) |
| NO (1) | NO974236L (cs) |
| NZ (1) | NZ303941A (cs) |
| PE (1) | PE7698A1 (cs) |
| PL (1) | PL322211A1 (cs) |
| SK (1) | SK121397A3 (cs) |
| TR (1) | TR199700948T1 (cs) |
| WO (1) | WO1996028424A1 (cs) |
| YU (1) | YU14196A (cs) |
| ZA (1) | ZA962009B (cs) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2164151T3 (es) * | 1995-06-06 | 2002-02-16 | Pfizer | N-(indol-2-carbonil)glicinamidas sustituidas y derivados como inhibidores de la glucogeno fosforilasa. |
| EP0873990A1 (en) * | 1995-09-22 | 1998-10-28 | Yoshitomi Pharmaceutical Industries, Ltd. | Benzoic acid compounds and medicinal use thereof |
| TW445263B (en) | 1996-02-29 | 2001-07-11 | Janssen Pharmaceutica Nv | Novel esters of 1,4-disubstituted piperidine derivatives |
| IL125658A0 (en) | 1997-08-18 | 1999-04-11 | Hoffmann La Roche | Ccr-3 receptor antagonists |
| US6339087B1 (en) | 1997-08-18 | 2002-01-15 | Syntex (U.S.A.) Llc | Cyclic amine derivatives-CCR-3 receptor antagonists |
| TW570920B (en) | 1998-12-22 | 2004-01-11 | Janssen Pharmaceutica Nv | 4-(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders |
| GB0211230D0 (en) * | 2002-05-16 | 2002-06-26 | Medinnova Sf | Treatment of heart failure |
| ATE539077T1 (de) * | 2003-09-03 | 2012-01-15 | Pfizer | Benzimidazolonverbindungen mit agonistischer wirkung am 5-ht4 rezeptor |
| TW200533348A (en) * | 2004-02-18 | 2005-10-16 | Theravance Inc | Indazole-carboxamide compounds as 5-ht4 receptor agonists |
| US8309575B2 (en) | 2004-04-07 | 2012-11-13 | Theravance, Inc. | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists |
| US7728006B2 (en) * | 2004-04-07 | 2010-06-01 | Theravance, Inc. | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists |
| TWI351282B (en) | 2004-04-07 | 2011-11-01 | Theravance Inc | Quinolinone-carboxamide compounds as 5-ht4 recepto |
| US7737163B2 (en) * | 2004-06-15 | 2010-06-15 | Pfizer Inc. | Benzimidazolone carboxylic acid derivatives |
| AP2418A (en) * | 2004-06-15 | 2012-06-04 | Pfizer | Benzimidazolone carboxylic acid derivatives. |
| EA200801608A1 (ru) * | 2004-06-15 | 2008-10-30 | Пфайзер Инк. | Производные бензимидазолонкарбоновой кислоты |
| JP2008509088A (ja) * | 2004-09-02 | 2008-03-27 | ファイザー株式会社 | ベンズイミダゾロンカルボン酸誘導体 |
| WO2006052889A2 (en) * | 2004-11-05 | 2006-05-18 | Theravance, Inc. | Quinolinone-carboxamide compounds |
| DE602005016446D1 (de) * | 2004-11-05 | 2009-10-15 | Theravance Inc | 5-HT4-Rezeptoragonistenverbindungen |
| CN101080406A (zh) * | 2004-12-22 | 2007-11-28 | 施万制药 | 吲唑－甲酰胺化合物 |
| NZ556627A (en) * | 2005-02-22 | 2010-09-30 | Pfizer | Oxyindole derivatives as 5HT4 receptor agonists |
| MX2007010769A (es) * | 2005-03-02 | 2008-03-07 | Theravance Inc | Compuestos de quinolina como agonistas de receptor 5-ht4. |
| WO2006133104A2 (en) * | 2005-06-07 | 2006-12-14 | Theravance, Inc. | Benzoimidazolone-carboxamide compounds as 5-ht4 receptor agonists |
| MY143574A (en) * | 2005-11-22 | 2011-05-31 | Theravance Inc | Carbamate compounds as 5-ht4 receptor agonists |
| US8642772B2 (en) | 2008-10-14 | 2014-02-04 | Sk Biopharmaceuticals Co., Ltd. | Piperidine compounds, pharmaceutical composition comprising the same and its use |
| US8232315B2 (en) * | 2009-06-26 | 2012-07-31 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating drug addiction and improving addiction-related behavior |
| EP2496228B1 (en) | 2009-11-06 | 2014-01-15 | SK Biopharmaceuticals Co., Ltd. | Methods for treating attention-deficit/hyperactivity disorder |
| CA2779442A1 (en) | 2009-11-06 | 2011-05-12 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating fibromyalgia syndrome |
| NZ604423A (en) | 2010-06-24 | 2015-01-30 | Alkermes Pharma Ireland Ltd | Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives |
| US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| US8623913B2 (en) | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9103862D0 (en) * | 1991-02-25 | 1991-04-10 | Glaxo Group Ltd | Chemical compounds |
| GB9204565D0 (en) * | 1992-03-03 | 1992-04-15 | Smithkline Beecham Plc | Pharmaceuticals |
| EP0664794A1 (en) * | 1992-10-16 | 1995-08-02 | Smithkline Beecham Plc | N-alkylpiperidinyl-4-methyl carboxylic esters/amides of condensed ring systems as 5-ht4 receptor antagonists |
| EP0774460A1 (en) * | 1994-03-30 | 1997-05-21 | Yoshitomi Pharmaceutical Industries, Ltd. | Benzoic acid compound and use thereof as medicine |
-
1995
- 1995-03-14 IT IT95MI000491A patent/IT1275903B1/it active IP Right Grant
-
1996
- 1996-03-04 BR BR9607347A patent/BR9607347A/pt not_active Application Discontinuation
- 1996-03-04 NZ NZ303941A patent/NZ303941A/en unknown
- 1996-03-04 CA CA002209904A patent/CA2209904C/en not_active Expired - Lifetime
- 1996-03-04 US US08/913,425 patent/US6002009A/en not_active Expired - Lifetime
- 1996-03-04 TR TR97/00948T patent/TR199700948T1/xx unknown
- 1996-03-04 SK SK1213-97A patent/SK121397A3/sk unknown
- 1996-03-04 EP EP96907342A patent/EP0815080B1/en not_active Expired - Lifetime
- 1996-03-04 AT AT96907342T patent/ATE269304T1/de active
- 1996-03-04 DE DE69632724T patent/DE69632724T2/de not_active Expired - Lifetime
- 1996-03-04 ES ES96907342T patent/ES2224159T3/es not_active Expired - Lifetime
- 1996-03-04 JP JP52723396A patent/JP4021477B2/ja not_active Expired - Lifetime
- 1996-03-04 WO PCT/EP1996/000903 patent/WO1996028424A1/en active IP Right Grant
- 1996-03-04 AU AU51010/96A patent/AU5101096A/en not_active Abandoned
- 1996-03-04 CZ CZ972859A patent/CZ285997A3/cs unknown
- 1996-03-04 EE EE9700202A patent/EE9700202A/xx unknown
- 1996-03-04 KR KR1019970706380A patent/KR19980702972A/ko not_active Withdrawn
- 1996-03-04 PL PL96322211A patent/PL322211A1/xx unknown
- 1996-03-05 PE PE1996000151A patent/PE7698A1/es not_active Application Discontinuation
- 1996-03-08 AR ARP960101670A patent/AR002967A1/es unknown
- 1996-03-11 YU YU14196A patent/YU14196A/sh unknown
- 1996-03-12 IL IL11744696A patent/IL117446A0/xx unknown
- 1996-03-13 HR HRMI95A000491A patent/HRP960116A2/hr not_active Application Discontinuation
- 1996-03-13 ZA ZA9602009A patent/ZA962009B/xx unknown
- 1996-03-13 CO CO96012408A patent/CO4700521A1/es unknown
-
1997
- 1997-07-01 BG BG101711A patent/BG101711A/xx unknown
- 1997-09-12 NO NO974236A patent/NO974236L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HRP960116A2 (en) | 1997-10-31 |
| JP4021477B2 (ja) | 2007-12-12 |
| ITMI950491A1 (it) | 1996-09-14 |
| DE69632724T2 (de) | 2005-07-07 |
| YU14196A (sh) | 1999-03-04 |
| MX9706826A (es) | 1997-11-29 |
| PL322211A1 (en) | 1998-01-19 |
| KR19980702972A (ko) | 1998-09-05 |
| ZA962009B (en) | 1997-09-15 |
| CO4700521A1 (es) | 1998-12-29 |
| EP0815080B1 (en) | 2004-06-16 |
| NO974236D0 (no) | 1997-09-12 |
| DE69632724D1 (de) | 2004-07-22 |
| CA2209904C (en) | 2007-11-13 |
| WO1996028424A1 (en) | 1996-09-19 |
| NO974236L (no) | 1997-09-12 |
| JPH11501640A (ja) | 1999-02-09 |
| CA2209904A1 (en) | 1996-09-19 |
| ATE269304T1 (de) | 2004-07-15 |
| AR002967A1 (es) | 1998-05-27 |
| EE9700202A (et) | 1998-02-16 |
| AU5101096A (en) | 1996-10-02 |
| ES2224159T3 (es) | 2005-03-01 |
| EP0815080A1 (en) | 1998-01-07 |
| CZ285997A3 (cs) | 1998-02-18 |
| TR199700948T1 (xx) | 1998-03-21 |
| PE7698A1 (es) | 1998-03-11 |
| NZ303941A (en) | 1998-11-25 |
| IT1275903B1 (it) | 1997-10-24 |
| SK121397A3 (en) | 1998-02-04 |
| ITMI950491A0 (it) | 1995-03-14 |
| BR9607347A (pt) | 1997-12-30 |
| US6002009A (en) | 1999-12-14 |
| IL117446A0 (en) | 1996-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG101711A (en) | Di-substituted 1,4-piperidine esters and amides having 5-ht4 antagonistic activity | |
| HUT57202A (en) | Process for producing new pharmaceutically active 5-fluoro-2-///4-/cyclopropyl-methoxy/-2-pyridinyl/-methyl-sulfonyl/-1h-benzimidazol and pharmaceutical compositions containing them | |
| HUT49592A (en) | Process for producing bis/hydroxymethyl/-cyclobutyl-purines and pyrimidines, as well as pharmaceutical compositions comprising same | |
| HUT53888A (en) | Fungicides comprising pyrimidine derivatives as active ingredient and process for producing the active ingredients | |
| IL119488A (en) | Substituted 2, 4-imidazolidinediones, their production and pharmaceutical compositions containing them | |
| AU7360887A (en) | Pharmacologically active 1,5-diarly-3-substituted- pyrazoles and method for synthesizing the same | |
| AU2227992A (en) | Conformationally restricted biologically active peptides, methods for their production and uses thereof | |
| HUT52394A (en) | Process for producing ophthalmic pharmaceutical compositions comprising cyclosporin | |
| HUP9800273A3 (en) | Benzothiazine dioxides as endothelin antagonists, process for their production and pharmaceutical compositions containing the same | |
| HUT63374A (en) | Process for producing new benzoic acid derivatives having cardiovascular activity and pharmaceutical compositions comprising such active ingredient | |
| MX9801890A (es) | Nuevos compuestos antagonistas selectivos del receptor nk3 humano, procedimiento para su obtencion y composiciones farmaceuticas que los contienen. | |
| HUP0001165A3 (en) | Acylaminoalkenylene-amide derivatives as nk1 and nk2 antagonists, pharmaceutical compositions containing them and process for producing them | |
| CA2064373A1 (en) | Piperidine derivatives | |
| ZA934037B (en) | Novel biologically active eburnamenine derivatives, pharmaceutical compositions containing them and process for preparing same. | |
| HUT49370A (en) | Process for producing polypeptides and pharmaceutical compositions comprising same as active ingredient | |
| CA2071907A1 (en) | Bcrf1 proteins as inhibitors of interferon-y | |
| CA2220019A1 (en) | Pharmaceutical composition containing tiagabine hydrochloride and the process for its preparation | |
| HUT46660A (en) | Process for producing 3-alkoxy-2-amino-propyl-amines and pharmaceutical compositions comprising the same as active ingredient | |
| WO1990006943A3 (de) | Neue tnf-peptide | |
| AU657045B2 (en) | Tachykinin receptor antagonists, isoquinolones and their production | |
| AU5390294A (en) | Biologically active synthetic thyrotropin and cloned gene for producing same | |
| WO1993005807A3 (en) | Erythropoietin potentiating agents and methods for their use | |
| MY114693A (en) | Substituted benzenesulfonylureas and thioureas,processes for their preparation,their use for the production of pharmaceutical preparations, and pharmaceutical preparation containing them | |
| HUT58763A (en) | Process for producing reduced irreverzible bombezin antagonists and pharmaceutical compositions containing them as active components | |
| HUT53792A (en) | Microbiological process for producing agriculturally applicable active ingredients |